Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MGLL | Q99685 | 5/20 | 0.75 |
| ▸ | LTA4H | P09960 | 1/20 | 0.57 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.57 |
| ▸ | BCHE | P06276 | 3/20 | 0.55 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.52 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.52 |
| ▸ | CA12 | O43570 | 1/20 | 0.50 |
| ▸ | CA1 | P00915 | 1/20 | 0.50 |
| ▸ | CA2 | P00918 | 1/20 | 0.50 |
| ▸ | CA4 | P22748 | 1/20 | 0.50 |
| ▸ | CA5A | P35218 | 1/20 | 0.50 |
| ▸ | CA7 | P43166 | 1/20 | 0.50 |
| ▸ | CA9 | Q16790 | 1/20 | 0.50 |
| ▸ | CA5B | Q9Y2D0 | 1/20 | 0.50 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1172045 | 1.00 | MGLL (0.75) | MGLLLTA4HEPHX2BCHEFFAR1 | |
| SCHEMBL13159229 | 0.88 | MGLL (0.61) | MGLLLTA4HEPHX2BCHEFFAR1 | |
| SCHEMBL1172084 | 0.86 | MGLL (0.76) | MGLLBCHEFFAR1 | |
| SCHEMBL1172242 | 0.86 | MGLL (1.00) | MGLLLTA4HEPHX2BCHEFFAR1 | |
| SCHEMBL1171851 | 0.86 | MGLL (1.00) | MGLLLTA4HEPHX2BCHEFFAR1 | |
| SCHEMBL6752149 | 0.86 | MGLL (0.75) | MGLLLTA4HEPHX2BCHEFFAR1 | |
| SCHEMBL1171728 | 0.84 | MGLL (0.73) | MGLLLTA4HEPHX2BCHEFFAR1 | |
| SCHEMBL12040562 | 0.84 | LTA4H (0.77) | MGLLLTA4HEPHX2BCHEFFAR1 | |
| SCHEMBL1171731 | 0.84 | MGLL (0.73) | MGLLLTA4HEPHX2BCHEFFAR1 | |
| SCHEMBL7958344 | 0.84 | CA2 (0.53) | MGLLCA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9102622-B2 | Fatty acid amide hydrolase inhibitors | UNIVERSITY OF CONNECTICUT (US) | 2015-08-11 | — | — | US | disclosed |
| US-20110071178-A1 | Methods and Compounds for Modulating Cannabinoid Activity | NORTHEASTERN UNIVERSITY (US) | 2011-03-24 | — | — | US | disclosed |
| US-20110039874-A1 | MONOACYLGLYCEROL LIPASE INHIBITORS FOR MODULATION OF CANNABINOID ACTIVITY | NORTHEASTERN UNIVERSITY (US) | 2011-02-17 | — | — | US | disclosed |
| US-20100234379-A1 | Dual modulation of endocannabinoid transport and fatty-acid amide hydrolase for treatment of excitotoxicity | CONNECTICUT, UNIVERSITY OF | 2010-09-16 | — | — | US | disclosed |
| EP-2203412-A1 | MONOACYLGLYCEROL LIPASE INHIBITORS FOR MODULATION OF CANNABINOID ACTIVITY | NORTHEASTERN UNIVERSITY (US) | 2010-07-07 | — | — | EP | disclosed |
| EP-2203058-A1 | METHODS AND COMPOUNDS FOR MODULATING CANNABINOID ACTIVITY | NORTHEASTERN UNIVERSITY (US) | 2010-07-07 | — | — | EP | disclosed |
| US-20090306016-A1 | FATTY ACID AMIDE HYDROLASE INHIBITORS | UNIVERSITY OF CONNECTICUT | 2009-12-10 | — | — | US | disclosed |
| EP-2051964-A2 | FATTY ACID AMIDE HYDROLASE INHIBITORS | University of Connecticut (US) | 2009-04-29 | — | — | EP | disclosed |
| WO-2009052320-A1 | METHODS AND COMPOUNDS FOR MODULATING CANNABINOID ACTIVITY | NORTHEASTERN UNIVERSITY (US) | 2009-04-23 | — | — | WO | disclosed |
| WO-2009052319-A1 | MONOACYLGLYCEROL LIPASE INHIBITORS FOR MODULATION OF CANNABINOID ACTIVITY | NORTHEASTERN UNIVERSITY (US) | 2009-04-23 | — | — | WO | disclosed |
| WO-2008013963-A2 | FATTY ACID AMIDE HYDROLASE INHIBITORS | UNIVERSITY OF CONNECTICUT (US) | 2008-01-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110039874-A1 | MONOACYLGLYCEROL LIPASE INHIBITORS FOR MODULATION OF CANNABINOID ACTIVITY | MGLL, FAAH, FAAH2 | MGLL 1/4885LTA4H 79/4885EPHX2 238/4885 |
| US-20090306016-A1 | FATTY ACID AMIDE HYDROLASE INHIBITORS | FAAH, FAAH2, CNR2 | MGLL 20/4885LTA4H 192/4885EPHX2 43/4885 |
| US-20100234379-A1 | Dual modulation of endocannabinoid transport and fatty-acid amide hydrolase for treatment of excitotoxicity | FAAH, FAAH2, CNR2 | MGLL 161/4885LTA4H 314/4885EPHX2 294/4885 |
| US-20110071178-A1 | Methods and Compounds for Modulating Cannabinoid Activity | FAAH, FAAH2, CNR2 | MGLL 4/4885LTA4H 112/4885EPHX2 312/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.